cross-posted from : https://lemmy.zip/post/59750981

According to Goldman Sachs Research, 46 per cent of new drug molecules entering human trials worldwide in the first half of 2025 came from Chinese biopharma companies.

Official figures show that Chinese pharmaceutical companies signed 94 out-licensing deals in 2024. In 2025, that number surged to 157.

The value of those deals rose even faster, more than doubling from nearly US$52 billion to US$136 billion in just one year.